Experts in the management of multiple myeloma consider promising developments for the future of relapsed/refractory treatment, with special consideration to bispecific antibodies and CAR (chimeric ...
Key opinion leaders discuss why patients with multiple myeloma experience increasingly decreased response to therapy over time. C. Ola Landgren, MD, PhD: Hello and ...
Treatment with belantamab mafodotin plus bortezomib and dexamethasone reduced the risk of death by 51% compared with the combination of daratumumab, bortezomib, and dexamethasone. The Food and Drug ...
The FDA has granted accelerated approval to linvoseltamab (Lynozyfic, Regeneron) for relapsed or refractory multiple myeloma (MM) after at least four prior lines of therapy, including a proteasome ...
Association of Chronic Hepatitis B Infection and Antiviral Treatment With the Development of the Extrahepatic Malignancies: A Nationwide Cohort Study In the training set (N = 7,072), at a median ...
Risk factors such as LDH, del(17p), t(4;14), and 1q gain/amp(1q1), that predict overall survival and progression-free survival, were used to develop and validate an additive risk score for patients ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results